Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
For more information on side effects or to discuss any concerns, consult your healthcare provider
The difference is usually in the packaging or labeling
According to Reuters, this has resulted in many patients forgoing spending money in order to make up the difference
2014;162(2 Pt A):1021
US$ 27.15
US$ 22.64
US$ 25.94
US$ 29.88
US$ 28.05
US$ 21.33
US$ 24.19
